MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care. It develops and commercializes treatments for serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its products include Afrezza inhalation powder, an inhaled insulin for glycemic control in adults with diabetes; the V-Go wearable insulin delivery device; Tyvaso DPI for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and FUROSCIX, a furosemide injection for fluid buildup in chronic heart failure or chronic kidney disease. Its pipeline includes MNKD-201, a dry-powder formulation of nintedanib for idiopathic pulmonary fibrosis, and MNKD-701. The company has a collaboration and license agreement with United Therapeutics Corporation for Tyvaso DPI and a collaboration agreement with Thirona for pulmonary fibrosis. Incorporated in 1991, MannKind is headquartered in Danbury, Connecticut.
MannKind's pipeline wins and record sales offset dilution and royalty threat
▲
Afrezza pediatric approval drives 20% gain The FDA approved Afrezza, MannKind's inhaled insulin, for children aged 6 and up with diabetes. This opens a new market of over 350,000 young patients, and the stock has already risen about 20% since the news. Analysts see more upside ahead.
This is a major new approval that expands the market for MannKind's flagship product and has already boosted the stock.
▼
Competitor Tresmi threatens Tyvaso DPI royalty United Therapeutics introduced Tresmi, a competing inhaler for the same condition as Tyvaso DPI. MannKind earns a 9% royalty on Tyvaso DPI sales, which brought in $32.7 million last quarter. If Tresmi takes market share, that royalty income could shrink, hurting MannKind's profits.
This is a new competitive threat that could reduce a significant and reliable revenue stream for MannKind.
◆
$50 million private placement dilutes shares but funds CVR MannKind raised $50 million by selling new shares and warrants to investors led by Frazier Life Sciences. This brings in cash to fund a $45 million payment tied to the Furoscix ReadyFlow approval, but it also increases the number of shares outstanding, which can lower the value of each existing share.
This financing is a key capital event that affects MannKind's cash position and share count, with both positive and negative implications.
▲
Furoscix ReadyFlow approved and launched The FDA approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure and kidney disease. This adds a new product to MannKind's lineup and triggered a $45 million payment to the original developer. Early sales are growing quickly, up 43% from the prior quarter.
This is a new product approval that diversifies revenue and has already started contributing to growth.
▲
Inhaled nintedanib shows positive Phase 1b results MannKind's inhaled nintedanib for idiopathic pulmonary fibrosis (IPF) passed a mid-stage safety test, with no serious side effects. A larger Phase 2 trial is now enrolling patients. If successful, this could become a major new product, but it is still years from market.
This pipeline progress adds long-term growth potential and validates MannKind's inhalation technology.
▲
Record Q2 revenue and all 2026 catalysts achieved MannKind reported second-quarter revenue of $109.4 million, up 43% from a year ago, driven by strong product sales and royalties. The company hit all three of its 2026 goals: Afrezza pediatric approval, Furoscix ReadyFlow approval, and positive nintedanib data. It ended the quarter with $161 million in cash.
This earnings report confirms strong financial performance and execution, which supports the stock's value.
Q3 2026
▲4▼1
MannKind's pipeline wins and record sales offset dilution and royalty threat
▲
Afrezza pediatric approval drives 20% gain The FDA approved Afrezza, MannKind's inhaled insulin, for children aged 6 and up with diabetes. This opens a new market of over 350,000 young patients, and the stock has already risen about 20% since the news. Analysts see more upside ahead.
This is a major new approval that expands the market for MannKind's flagship product and has already boosted the stock.
▼
Competitor Tresmi threatens Tyvaso DPI royalty United Therapeutics introduced Tresmi, a competing inhaler for the same condition as Tyvaso DPI. MannKind earns a 9% royalty on Tyvaso DPI sales, which brought in $32.7 million last quarter. If Tresmi takes market share, that royalty income could shrink, hurting MannKind's profits.
This is a new competitive threat that could reduce a significant and reliable revenue stream for MannKind.
◆
$50 million private placement dilutes shares but funds CVR MannKind raised $50 million by selling new shares and warrants to investors led by Frazier Life Sciences. This brings in cash to fund a $45 million payment tied to the Furoscix ReadyFlow approval, but it also increases the number of shares outstanding, which can lower the value of each existing share.
This financing is a key capital event that affects MannKind's cash position and share count, with both positive and negative implications.
▲
Furoscix ReadyFlow approved and launched The FDA approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure and kidney disease. This adds a new product to MannKind's lineup and triggered a $45 million payment to the original developer. Early sales are growing quickly, up 43% from the prior quarter.
This is a new product approval that diversifies revenue and has already started contributing to growth.
▲
Inhaled nintedanib shows positive Phase 1b results MannKind's inhaled nintedanib for idiopathic pulmonary fibrosis (IPF) passed a mid-stage safety test, with no serious side effects. A larger Phase 2 trial is now enrolling patients. If successful, this could become a major new product, but it is still years from market.
This pipeline progress adds long-term growth potential and validates MannKind's inhalation technology.
▲
Record Q2 revenue and all 2026 catalysts achieved MannKind reported second-quarter revenue of $109.4 million, up 43% from a year ago, driven by strong product sales and royalties. The company hit all three of its 2026 goals: Afrezza pediatric approval, Furoscix ReadyFlow approval, and positive nintedanib data. It ended the quarter with $161 million in cash.
This earnings report confirms strong financial performance and execution, which supports the stock's value.
News & notes movingMNKD
United States
Biotech & Genomic Medicine
MannKind Licenses Rose Pharma's Inhaled GLP-1 ROSE-010 for Weight Loss
MannKind Corporation announced on September 9 a licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere, an inhaled, rapid-acting glucagon-like peptide-1 receptor agonist aimed at weight management. Under the deal, MannKind receives an equity stake in Rose Pharma, a board seat, and royalty rights on future sales, while Rose Pharma retains responsibility for clinical development, regulatory strategy, and commercialization; MannKind's role is limited to development and manufacturing support through completion of a Phase 1b study. ROSE-010 has already completed four human clinical trials, including a Phase 2a study in weight management that showed reductions in mealtime caloric intake and weight loss with a favorable gastrointestinal tolerability profile, plus a separate Phase 2a trial in irritable bowel syndrome that produced clinically meaningful, statistically significant pain relief. The agreement is light on detail, with no specific financial terms disclosed, and the program is years from any approval or royalty stream. The news lands alongside MannKind's second-quarter revenue of $109.4 million, up 43% from the same period in 2025, but also a swing to a net loss of $19 million from net income of $668,000 a year earlier, with selling, general and administrative expenses jumping 84% year over year to $58.3 million and cash and cash equivalents falling to $52.9 million as of June 30 from $74.9 million at the end of 2025.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
MNKD · Capital · Negative Q2 swung to a $19M net loss from $668K income, SG&A jumped 84%, and cash fell to $52.9M from $74.9M.
MNKD · Demand · Positive MannKind licenses in ROSE-010, gaining an equity stake, board seat, and royalty rights on a Phase 2a-validated inhaled GLP-1 weight-loss asset.
Rose Pharma Inc. · Demand · Positive Rose Pharma's ROSE-010 gets a development/manufacturing partner in MannKind while retaining clinical, regulatory, and commercialization control.
MannKind Reports Record Revenue and Major Catalysts in Q2 2026 Earnings Call
MannKind Corp reported second-quarter revenue of $109.4 million, up 43% year-over-year, driven by strong growth in marketed products and royalties. The company achieved all three major 2026 catalysts: Afrezza pediatric approval, Furo6 ReadyFlow approval, and positive Phase 1b data for nintedanib DPI in IPF patients. Afrezza pediatric launch shows early momentum with all 20 priority accounts writing prescriptions, while Furo6 revenue grew 43% quarter-over-quarter on a 49% increase in units sold. MannKind posted a GAAP net loss of $19 million compared to net income of $700,000 in the prior year quarter, and expects a $45 million CVR payment in Q3. The company raised $50 million in a pipe financing, ending the quarter with pro forma cash of $161 million.
MannKind Reports Positive Phase 1b Results for Inhaled Nintedanib in IPF
MannKind Corporation announced positive topline results from its Phase 1b INFLO-1 study of nintedanib dry powder inhalation in patients with idiopathic pulmonary fibrosis. The study met its primary objective, demonstrating that nintedanib DPI was generally safe and well tolerated, with no serious adverse events, no drug-related gastrointestinal side effects, no bronchospasm events, and no treatment discontinuations or dose reductions. Most patients experienced no cough, and reported cough events were predominantly mild, transient, and resolved. Across the completed Phase 1a and Phase 1b studies, a total of 48 individuals have received nintedanib DPI, including nearly 450 inhalations administered to people living with IPF. MannKind's global Phase 2 INFLO-2 study is actively enrolling patients with IPF, with approximately 210 participants expected across roughly 85 sites worldwide.
MannKind Gains FDA Approval for Furoscix ReadyFlow and Raises $50 Million
MannKind received U.S. Food and Drug Administration approval for Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure or chronic kidney disease, and concurrently completed a roughly $50 million private placement. The company's shares have returned 52.96% over the past 90 days but are down 26.25% year to date, with a one-year total shareholder return of 1.72%. A widely followed narrative on the stock pegs fair value at $7.59 per share versus the last close of $4.13, implying the stock is undervalued, though that view depends on a sharp swing into profitability and faster revenue growth. MannKind's current price-to-sales ratio of 3.5 times sits above the peer average of 2.9 times but below a fair ratio estimate of 5 times, reflecting mixed valuation signals. The company continues to face execution and concentration risk tied to Afrezza uptake and a narrow product portfolio.
MannKind announces $50 million private placement led by Frazier Life Sciences
MannKind Corporation has entered into a securities purchase agreement for a private placement expected to generate approximately $50 million in gross proceeds. The financing was led by Frazier Life Sciences, a longstanding biotech investment firm. MannKind is selling 10,440,838 shares of common stock and pre-funded warrants to purchase up to 2,412,632 shares, priced at $3.89 per share and $3.88 per pre-funded warrant. The company intends to use the net proceeds for general corporate purposes, including funding a $45 million contingent value rights payment triggered by the recent FDA approval of Furoscix ReadyFlow. The closing is expected on or about July 24, 2026, subject to customary conditions.
MannKind EVP David Thomson Sells 123,000 Shares, Mostly for Tax Obligations
MannKind Corporation EVP General Counsel & Secretary David Thomson sold 123,000 shares of common stock between July 15 and July 17, 2026, at a weighted average price of $4.08 per share, totaling about $500,000. The majority of the disposition, 98,426 shares, was a non-discretionary withholding by the company to cover tax liabilities from the vesting of performance-based restricted stock units that paid out at 83% of target after MannKind's total shareholder return ranked at the 41.5th percentile of the Russell 3000 Pharmaceutical & Biotechnology Index over a three-year period ending June 30, 2026. The remaining 24,109 shares were sold under a Rule 10b5-1 trading plan established on December 2, 2025. Following the transactions, Thomson directly holds nearly 798,000 shares valued at $3.21 million based on the July 17, 2026 close. The filing comes as MannKind faces uncertainty over its Tyvaso DPI royalty stream, which generated $32.7 million in the first quarter, after United Therapeutics launched a competing inhaler called Tresmi.
MannKind Insider Sale Was Tax-Driven, but 9% Tyvaso DPI Royalty Faces Threat from United Therapeutics' Tresmi
A MannKind insider sold 65,808 shares for about $269,000, but the transaction was a non-discretionary disposition to cover tax withholding obligations, not a voluntary market sale. The shares came from a May 2023 performance-based award that vested at 83% of target after the company met stock-price and total-shareholder-return goals relative to the Russell 3000 Pharmaceutical & Biotechnology Index. Following the sale, Chief People & Workplace Officer Stuart A. Tross still directly holds roughly 1.1 million shares. More significant for investors is the risk to MannKind's 9% royalty on Tyvaso DPI, which generated $32.7 million in the first quarter, after United Therapeutics unveiled a competing soft-mist inhaler called Tresmi that its CEO labeled a category killer.
MannKind CEO Michael Castagna Sells 363,200 Shares to Cover Tax Obligations
MannKind Corporation CEO Michael Castagna disposed of 363,200 shares on July 15, 2026, in a non-discretionary transaction to satisfy tax withholding obligations tied to the vesting of restricted stock units. The sale, valued at approximately $1.5 million based on a weighted average price of $4.09 per share, represented 13% of his direct equity holdings. Following the transaction, Castagna retains 2,433,779 shares directly, maintaining significant exposure to the company's long-term performance. The underlying RSUs vested after MannKind achieved 83% of performance targets linked to total shareholder return and stock price benchmarks set in May 2023.
MannKind Corporation Gains 20% Since Afrezza FDA Approval for Children
MannKind Corporation has gained roughly 20% since the FDA approved Afrezza, an inhaled insulin, for children and adolescents aged 6 and older with type 1 or type 2 diabetes. The approval, announced on May 29, expands the drug's use beyond adults, where it was already approved. More than 350,000 children and adolescents in the US have diabetes and most need lifelong insulin therapy. The drug uses the company's Technosphere platform to deliver insulin via the lungs for rapid absorption, and the approval was based on the INHALE-1 trial plus two decades of additional safety and efficacy data. On June 23, MannKind also announced a grant from Breakthrough T1D to support the INHALE-1ST clinical study, which tests whether Afrezza can be used soon after a type 1 diabetes diagnosis in kids. Analysts' 12-month average price target suggests more than 54% upside from the current level.
MannKind Corporation's diversified pipeline and royalty streams support $8.50 price target, implying 134% upside
A bullish thesis on MannKind Corporation highlights the company's transformation into a diversified healthcare business with three revenue streams: Afrezza inhaled insulin, Furoscix for heart failure, and high-margin royalties from Tyvaso DPI through its partnership with United Therapeutics. Management has shifted focus toward pulmonary and cardiovascular diseases and broadened the revenue base with the acquisition of scPharmaceuticals. Financially, MannKind generated $349 million in 2025 revenue, grew sales by 22%, eliminated its remaining debt, and held $134 million in cash as of March 2026. A risk-adjusted sum-of-the-parts valuation derives a target price of $8.50 per share, implying approximately 134% upside from the June 24th price of $3.84, with a blue-sky range of $10 to $12 per share if regulatory and clinical milestones are met.
MNKD · Capital · Positive Article is a bullish thesis on MannKind, highlighting revenue growth, debt elimination, and $8.50 price target with 134% upside.
UTHR · Demand · Positive MannKind's high-margin royalties from Tyvaso DPI through partnership with United Therapeutics are mentioned as a revenue stream, implying positive demand for United's product.
MannKind Awarded Breakthrough T1D Grant to Support Pediatric Inhaled Insulin Trial
MannKind Corporation has been awarded a grant from Breakthrough T1D to support the ongoing INHALE-1ST clinical study evaluating Afrezza in youth newly diagnosed with type 1 diabetes. The grant comes through Breakthrough T1D's Industry Discovery and Development Partnership program and will help fund the multi-center trial assessing safety and efficacy of Afrezza combined with once-daily basal insulin in patients aged 10 to under 18. MannKind recently completed enrollment of the pilot phase of the study, which follows participants for 13 weeks with an optional extension up to 26 weeks. The collaboration underscores growing interest in inhaled insulin as a new option for pediatric diabetes care, building on the FDA's May 2026 approval of Afrezza for patients aged 6 and older.
MNKD · Technology · Positive Grant from Breakthrough T1D supports pediatric inhaled insulin trial, expanding Afrezza's potential use in youth with type 1 diabetes.
USA